Overview
Availability
- Dr Mark Effron is:
- Available for supervision
Works
Search Professor Mark Effron’s works on UQ eSpace
2004
Conference Publication
Physical and chemical compatibility of drotrecogin alfa (activated) with 34 drugs during simulated Y-site administration
Mann, HJ, Demmon, SL, Boelk, DA, Payne, CA, Effron, MB, Rajagopalan, N, Williams, MD, Beck, GM and Gopalrathnam, G (2004). Physical and chemical compatibility of drotrecogin alfa (activated) with 34 drugs during simulated Y-site administration. 38th Midyear Clinical Meeting of the American-Society-of-Health-System-Pharmacists, New Orleans La, Dec 08-09, 2003. BETHESDA: AMER SOC HEALTH-SYSTEM PHARMACISTS. doi: 10.1093/ajhp/61.24.2664
2004
Conference Publication
Clinical use of drotrecogin alfa (activated): Patients treated in the XEUS study differ from high risk prowess patients
Rickert, T, Jay, S, Michael, C, Karen, S, Pamela, L, Effron, M, Linde-Zwirble, W and Zeckel, M (2004). Clinical use of drotrecogin alfa (activated): Patients treated in the XEUS study differ from high risk prowess patients. CHEST 2004 Conference, Seattle Wa, Oct 23-28, 2004. NORTHBROOK: AMER COLL CHEST PHYSICIANS. doi: 10.1378/chest.126.4_MeetingAbstracts.865S-a
2004
Conference Publication
Safety of drotrecogin alfa (activated): Results of Xeus, a prospective multicenter observational study
Karen, S, Lipsett, P, Effron, M, Rickert, T, Zeckel, M, Linde-Zwirble, W, Steingrub, J and Cheatham, M (2004). Safety of drotrecogin alfa (activated): Results of Xeus, a prospective multicenter observational study. CHEST 2004 Conference, Seattle Wa, Oct 23-28, 2004. NORTHBROOK: AMER COLL CHEST PHYSICIANS. doi: 10.1378/chest.126.4_MeetingAbstracts.724S-a
2004
Journal Article
Final results of the ReoPro Readministration Registry
Dery, JP, Braden, GA, Lincoff, AM, Kereiakes, DJ, Browne, K, Little, T, George, BS, Sane, DC, Cines, DB, Effron, MB, Mascelli, MA, Langrall, MA, Damaraju, L, Barnathan, ES and Tcheng, JE (2004). Final results of the ReoPro Readministration Registry. American Journal of Cardiology, 93 (8), 979-984. doi: 10.1016/j.amjcard.2003.12.051
2003
Journal Article
Feasibility and implications of an early discharge strategy after percutaneous intervention with Abciximab in acute myocardial infarction (the CADILLAC trial)
Kandzari, DE, Tcheng, JE, Cohen, DJ, Bakhai, A, Grines, CL, Cox, DA, Effron, M, Stuckey, T, Griffin, JJ, Turco, M, Carroll, JD, Fahy, M, Mehran, R and Stone, GW (2003). Feasibility and implications of an early discharge strategy after percutaneous intervention with Abciximab in acute myocardial infarction (the CADILLAC trial). American Journal of Cardiology, 92 (7), 779-784. doi: 10.1016/S0002-9149(03)00882-8
2003
Journal Article
Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction - The Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial
Tcheng, JE, Kandzari, DE, Grines, CL, Cox, DA, Effron, MB, Garcia, E, Griffin, JJ, Guagliumi, G, Stuckey, T, Turco, M, Fahy, M, Lansky, AJ, Mehran, R and Stone, GW (2003). Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction - The Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. Circulation, 108 (11), 1316-1323. doi: 10.1161/01.CIR.0000087601.45803.86
2003
Conference Publication
Abciximab readministration: Final results of the Reopro(fi) read ministration registry
Dery, JP, Braden, GA, Lincoff, AM, Kereiakes, DJ, Browne, KF, Little, T, George, BS, Effron, MB, Mascelli, MA, Langrall, MA, Damaraju, L, Barnathan, ES and Tcheng, JE (2003). Abciximab readministration: Final results of the Reopro(fi) read ministration registry. 52nd Annual Scientific Session of the American-College-of-Cardiology, Chicago Illinois, Mar 30-Apr 02, 2003. NEW YORK: ELSEVIER SCIENCE INC.
2003
Conference Publication
Benefits and risks of abciximab use in primary Angioplasty for acute myocardial infarction: The CADILLAC trial
Kandzari, DE, Tcheng, JE, Grines, CL, Effron, M, Cox, DA, Garcia, E, Griffin, JJ, Guagliumi, G, Stuckey, TD, Turco, M, Lansky, AJ, Mehran, R and Stone, GW (2003). Benefits and risks of abciximab use in primary Angioplasty for acute myocardial infarction: The CADILLAC trial. 52nd Annual Scientific Session of the American-College-of-Cardiology, Chicago Illinois, Mar 30-Apr 02, 2003. NEW YORK: ELSEVIER SCIENCE INC.
2003
Conference Publication
Safety of an early discharge strategy following primary intervention with adjunctive glycoprotein IIb/IIIa inhibition: The CADILLAC trial
Kandzari, DE, Tcheng, JE, Grines, CL, Cohen, DJ, Bakhai, A, Cox, DA, Stuckey, TD, Effron, M, Griffin, JJ, Turco, M, Carroll, JD, Fahy, M, Mehran, R and Stone, GW (2003). Safety of an early discharge strategy following primary intervention with adjunctive glycoprotein IIb/IIIa inhibition: The CADILLAC trial. 52nd Annual Scientific Session of the American-College-of-Cardiology, Chicago Illinois, Mar 30-Apr 02, 2003. NEW YORK: ELSEVIER SCIENCE INC.
2002
Conference Publication
Tadalafil does not affect time to ischemia during exercise stress testing in patients with coronary artery disease
Patterson, D, MacDonald, TM, Effron, MB, Emmick, JT, Mitchell, MI and Kloner, RA (2002). Tadalafil does not affect time to ischemia during exercise stress testing in patients with coronary artery disease. American-Heart-Association Abstracts From Scientific Sessions, Chicago Illinois, Nov 17-20, 2002. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS.
2002
Conference Publication
Cost-effectiveness of coronary stenting and abciximab for patients with AMI: Results from the CADILLAC trial
Bakhai, A, Stone, GW, Murphy, SA, Githiora, L, Berezin, RH, Gedney, S, Hormel, P, Effron, M, Cox, DA, Tcheng, JE, Grines, CL and Cohen, DJ (2002). Cost-effectiveness of coronary stenting and abciximab for patients with AMI: Results from the CADILLAC trial. American-Heart-Association Abstracts From Scientific Sessions, Chicago Illinois, Nov 17-20, 2002. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS.
2001
Conference Publication
A current review of olanzapine's safety in the geriatric patient: from pre-clinical pharmacology to clinical data
Kennedy, JS, Bymaster, FP, Schuh, L, Calligaro, DO, Nomikos, G, Felder, CC, Bernauer, M, Kinon, BJ, Baker, RW, Hay, D, Roth, HJ, Dossenbach, M, Kaiser, C, Beasley, CM, Holcombe, JH, Effron, MB and Breier, A (2001). A current review of olanzapine's safety in the geriatric patient: from pre-clinical pharmacology to clinical data. Symposium on Management of Psychoses in Older People, Barcelona Spain, Nov, 2000. W SUSSEX: JOHN WILEY & SONS LTD. doi: 10.1002/1099-1166(200112)16:1+3.0.CO;2-5
2001
Conference Publication
Abciximab readministration - Results of the ReoPro readministration registry
Tcheng, JE, Kereiakes, DJ, Lincoff, AM, George, BS, Kleiman, NS, Sane, DC, Cines, DB, Jordan, RE, Mascelli, MA, Langrall, MA, Damaraju, L, Schantz, A, Effron, MB and Braden, GA (2001). Abciximab readministration - Results of the ReoPro readministration registry. 71st Scientific Session of the American-Heart-Association, Dallas Tx, Nov 08-12, 1998. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. doi: 10.1161/hc3301.094533
2001
Conference Publication
Abciximab use during percutaneous intervention in patients with acute myocardial infarction improves early and late clinical outcomes: Final results of the CADILLAC trial
Tcheng, JE, Effron, M, Grines, CL, Garcia, E, Cox, D, Stuckey, T, Carroll, J, Guagliumi, G, Rutherford, B, Lansky, AJ, Esente, P, Griffin, J and Stone, GW (2001). Abciximab use during percutaneous intervention in patients with acute myocardial infarction improves early and late clinical outcomes: Final results of the CADILLAC trial. NEW YORK: ELSEVIER SCIENCE INC.
2001
Conference Publication
A prospective, multicenter, international randomized trial comparing four reperfusion strategies in acute myocardial infarction: Principal report of the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial
Stone, GW, Grines, CL, Cox, DA, Garcia, E, Tcheng, JE, Stuckey, T, Carroll, J, Guagliumi, G, Rutherford, B, Johnson, G, Effron, M, Esente, P, Lansky, AJ and Griffin, J (2001). A prospective, multicenter, international randomized trial comparing four reperfusion strategies in acute myocardial infarction: Principal report of the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. NEW YORK: ELSEVIER SCIENCE INC.
2000
Conference Publication
Abciximab improves outcomes in patients of all ages: Pooled analysis of 4 phase 3 trials
Effron, MB, Booth, J, Balog, C and Cabot, C (2000). Abciximab improves outcomes in patients of all ages: Pooled analysis of 4 phase 3 trials. NEW YORK: EXCERPTA MEDICA INC.
2000
Journal Article
Abciximab, ticlopidine, and concomitant abciximab-ticlopidine therapy: Ex vivo platelet aggregation inhibition profiles in patients undergoing percutaneous coronary interventions
Kleiman, NS, Grazeiadei, N, Maresh, K, Taylor, RJ, Frederick, B, Lance, ET, Effron, MB, Jordan, RE and Mascelli, MA (2000). Abciximab, ticlopidine, and concomitant abciximab-ticlopidine therapy: Ex vivo platelet aggregation inhibition profiles in patients undergoing percutaneous coronary interventions. American Heart Journal, 140 (3), 492-501. doi: 10.1067/mhj.2000.109220
2000
Conference Publication
Comparison of GP IIb/IIIa receptor inhibitors in patients undergoing percutaneous coronary interventions: a meta-analysis
Chadbourne, EB, Allen, IE, Luo, D, Gordon, MJ, Reid, P, Wilson, MG, Effron, MB, Perkins, LE, Jamal, HH and Ross, SD (2000). Comparison of GP IIb/IIIa receptor inhibitors in patients undergoing percutaneous coronary interventions: a meta-analysis. LONDON: W B SAUNDERS CO LTD.
2000
Journal Article
Abciximab and bleeding during coronary surgery: Results from the EPILOG and EPISTENT trials
Lincoff, AM, LeNarz, LA, Despotis, GJ, Smith, PK, Booth, JE, Raymond, RE, Sapp, SK, Cabot, CF, Tcheng, JE, Califf, RM, Effron, MB and Topol, EJ (2000). Abciximab and bleeding during coronary surgery: Results from the EPILOG and EPISTENT trials. Annals of Thoracic Surgery, 70 (2), 516-526. doi: 10.1016/S0003-4975(00)01343-6
2000
Journal Article
Effects of abciximab, ticlopidine, and combined abciximab/ticlopidine therapy on platelet and leukocyte function in patients undergoing coronary angioplasty
Fredrickson, BJ, Turner, NA, Kleiman, NS, Graziadei, N, Maresh, K, Mascelli, MA, Effron, MB and McIntire, LV (2000). Effects of abciximab, ticlopidine, and combined abciximab/ticlopidine therapy on platelet and leukocyte function in patients undergoing coronary angioplasty. Circulation, 101 (10), 1122-1129. doi: 10.1161/01.CIR.101.10.1122
Supervision
Availability
- Dr Mark Effron is:
- Available for supervision
Before you email them, read our advice on how to contact a supervisor.
Media
Enquiries
For media enquiries about Dr Mark Effron's areas of expertise, story ideas and help finding experts, contact our Media team: